GlassScriptPhysician profile
Laura Bednar
NPI 1043044811
$1,446.46
in general payments reported to CMS, 2019-2025
22 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $321 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $169.25 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $158.29 | 2024-2025 | |
| Axsome Therapeutics, INC. | $149.82 | 2025 | Auvelity |
| Novo Nordisk INC | $122.31 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $120.43 | 2025 | |
| Astellas Pharma US INC | $116.88 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.73 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $60.19 | 2025 | |
| Lilly USA, LLC | $60.14 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $55.86 | 2024-2025 | Vyepti, Rexulti |
| Corcept Therapeutics | $49.91 | 2025 | Korlym |
| Exact Sciences Corporation | $33.86 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $31.56 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $30.96 | 2025 | Trelegy Ellipta |
| Amgen INC. | $29.88 | 2024-2025 | Evenity, Repatha, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $29.49 | 2024 | Azstarys |
| Xeris Pharmaceuticals, INC. | $29.01 | 2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $24.10 | 2024 | Ingrezza |
| Dexcom, INC. | $22.99 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $17.39 | 2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.74 | 2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $13.67 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bednar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.